Colorectal Cancer-Targeted Exosome Modification Service
- Develop tailored exosome modification strategies according to client targets, therapeutic molecules, and applications.
- Multiple approach comparisons: genetic membrane engineering vs. chemical conjugation vs. hybrid loading technologies.
- Custom cultivation of source cells: Using CRC-specific cells (e.g., colon epithelial stem cells) or universal sources (e.g., mesenchymal stem cells) to isolate high-purity exosomes.
- Targeting modifications: Introducing CRC-targeting ligands (e.g., RGD peptides, anti-CEA single-chain antibodies) via transfection or chemical cross-linking.
- Drug loading: Efficient encapsulation of small molecules/nucleic acids through electroporation, freeze-thaw cycles, or Exofect reagents.
- Physical characterization: Nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and Zeta potential measurements.
- Targeting validation: In vitro co-culture assays (cellular uptake efficiency), in vivo tracing in tumor-bearing animal models.
- Efficacy assessment: Evaluating inhibitory effects on CRC cell proliferation and migration, and EMT markers (E-cadherin/Vimentin).
- Offering genetic integration, chemical conjugation, and hybrid loading technologies adapted to varied research needs.
- Proprietary technologies significantly enhance exosome yields and drug-loading efficiency (3-5 times increase).
- Deep expertise in oncology and nanomedicine, tailored exosome strategies aligned with CRC-specific mechanisms.
- End-to-end service from mechanistic studies to animal model validation.
- Standardized processes for accelerated delivery timelines (as fast as 8 weeks for targeted validation).
- Flexible services from pre-pilot development to pilot-scale production.
Exosomes are nanoscale extracellular vesicles (30–150 nm) actively secreted by cells, naturally carrying bioactive molecules including proteins, nucleic acids (e.g., mRNA, miRNA), and lipids. Due to their low immunogenicity, excellent biocompatibility, and capability of penetrating tissue barriers, exosomes have emerged as highly promising intelligent drug delivery vehicles. Through specific interactions mediated by membrane proteins or receptor ligands, exosomes precisely recognize diseased cells and deliver therapeutic payloads. Their vesicular structures effectively encapsulate chemotherapy drugs, nucleic acids, and antibodies, protecting them from enzymatic degradation and immune clearance, thus prolonging circulation time. Additionally, exosomes can traverse barriers such as the tumor microenvironment or blood-brain barrier, delivering therapeutic agents to previously inaccessible sites.
Zhang, M. et al. Signal Transduct Target Ther. 2023.
Figure 1. Genetically Engineered Exosomes in Various Cancers
Colorectal cancer (CRC) treatment faces significant challenges due to drug resistance, instability of nucleic acid therapeutics, and inefficient delivery in the complex tumor microenvironment. Engineered exosomes offer an innovative solution. Surface modification with CRC-specific ligands (e.g., folate receptors, EGFR antibodies, or sAPRIL-binding peptides) significantly enhances tumor-targeted drug accumulation. Methods such as electroporation, sonication, or genetic engineering enable efficient encapsulation of chemotherapy agents or siRNAs, enabling stable delivery and synergistic regulation—for example, combining chemotherapeutic drugs with immune modulators to inhibit tumor growth, block metastatic pathways, and overcome drug resistance from multiple angles.
Zhang, M. et al. Signal Transduct Target Ther. 2023.
Figure2. The Common Strategies of Exosome Engineering
Strategies for Colorectal Cancer-Targeted Exosome Modification:
1. Surface Ligand Engineering
Genetic or chemical conjugation of targeting peptides/antibodies (e.g., folate, anti-EpCAM) onto exosome surfaces.
2. Membrane Fusion Technology
Hybrid systems combining liposomes and exosomes to enhance drug-loading capacity and targeting specificity.
3. Customized Payload
Loading small-molecule inhibitors or gene-editing tools targeting critical CRC pathways (e.g., Wnt/β-catenin, mTOR).
Services at MtoZ Biolabs
MtoZ Biolabs provides comprehensive solutions from targeting design and exosome preparation to functional validation, dedicated to developing highly efficient and safe exosome-based delivery systems for colorectal cancer research teams. Our service is designed specifically to address:
1. Drug Delivery Barriers
Optimizing encapsulation efficiency and stability of chemotherapy drugs or nucleic acids.
2. Insufficient Targeting
Improving exosome specificity towards CRC tumors through precise modifications.
3. Mechanism Research Support
Verifying regulatory effects of engineered exosomes on specific signaling pathways (e.g., EMT, glycolysis).
Analysis Workflow
1. Consultation and Strategy Customization
2. Exosome Preparation and Modification
3. Quality Control and Functional Validation
Service Advantages
1. Multidimensional Engineering Capabilities
2. Interdisciplinary Expertise
3. Rapid Response and Cost Control
Applications
1. Enhanced Drug Delivery Efficiency
Targeted exosomes precisely deliver chemotherapeutics (e.g., oxaliplatin) or gene therapies (e.g., siKRAS) directly to CRC cells, minimizing liver and kidney toxicity.
2. Metastasis Suppression
Delivery of EMT inhibitors (e.g., siSnail) effectively blocks CRC cell invasiveness.
3. Drug Resistance Reversal
Co-delivery of chemotherapeutics and resistance-reversal agents (e.g., miR-34a) to synergistically kill drug-resistant cells.
Case Study
1. AS1411 Aptamer-Functionalized Exosomes in the Targeted Delivery of Doxorubicin in Fighting Colorectal Cancer
This study developed AS1411 aptamer-functionalized exosomes (DOX-Apt-Exo) for targeted doxorubicin delivery in colorectal cancer. HEK293-derived exosomes were loaded with doxorubicin, achieving approximately 13% encapsulation efficiency. AS1411 aptamers were conjugated to the exosome surface to target nucleolin-overexpressing cancer cells. In vitro experiments demonstrated enhanced cellular uptake and cytotoxicity of DOX-Apt-Exo. In vivo studies in mouse models showed effective tumor growth suppression and prolonged retention of the drug at the tumor site through ligand-receptor interactions. The results suggest that AS1411-functionalized exosomes are a promising and safe platform for targeted drug delivery in colorectal cancer. Colorectal Cancer-Targeted Exosome Modification Service offers engineered exosome solutions for precise colorectal cancer treatment. By modifying exosome surfaces with targeted aptamers or ligands, we enable site-specific drug delivery to colorectal cancer cells, enhancing therapeutic efficacy and minimizing systemic toxicity. Our service supports the development of targeted delivery systems, offering a reliable solution for effective cancer treatment.
Hosseini, NF. et al. Biomed Pharmacother. 2022.
Figure 2. In vivo FAM-Labeled AS1411-Exosomes Biodistribution in Tumor Bearing Mice by Animal Imaging
2. Anticancer effect of hUC-MSC-derived exosome-mediated delivery of PMO-miR-146b-5p in colorectal cancer
This study explores the anticancer effects of human umbilical cord mesenchymal cell (hUC-MSC)-derived exosomes for targeted delivery of PMO-miR-146b-5p antisense oligonucleotide (ASO) in colorectal cancer. The anti-miR-146b-5p ASO (PMO-146b) was conjugated to exosomes through an anchor peptide (CP05) that recognizes the exosomal surface marker CD63, forming the ePPMO-146b complex. In vitro, ePPMO-146b successfully inhibited cell proliferation, migration, and epithelial-mesenchymal transition in SW620 cells. In vivo, it showed significant antitumor effects in a colon cancer mouse model, with enhanced accumulation in tumor tissue, highlighting its potential as a safe and effective drug delivery system. Colorectal Cancer-Targeted Exosome Modification Service provides engineered exosomes for precise drug delivery in colorectal cancer treatment. By modifying exosome surfaces with target-specific ligands or peptides, we ensure targeted delivery of therapeutic agents to colorectal cancer cells, enhancing efficacy and minimizing systemic toxicity. This service offers a reliable solution for developing novel, effective drug delivery systems tailored for cancer therapies.
Yu, S. et al. Drug Deliv Transl Res. 2024.
Figure 3. In vivo Antitumor Effect and the Biodistribution of ePPMO-146b in Mice
Exosome-driven targeted therapy has emerged as a frontier breakthrough in colorectal cancer precision medicine. Leveraging deep expertise in targeted delivery technologies and robust process development platforms, MtoZ Biolabs provides highly targeted, stable engineered exosome solutions for research institutions and pharmaceutical companies, accelerating the translation of innovative CRC therapies from laboratory research to clinical application. Let’s collaborate to overcome traditional delivery limitations and usher in a new era of colorectal cancer treatment!
How to order?
